244 related articles for article (PubMed ID: 6791982)
1. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
[TBL] [Abstract][Full Text] [Related]
2. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents.
Fujii S; Kitano S; Ikenaka K; Shirasaka T
Gan; 1979 Apr; 70(2):209-14. PubMed ID: 381088
[TBL] [Abstract][Full Text] [Related]
3. [Antineoplastic effect of UFT therapy (uracil-FT-207 combination therapy) on experimental pancreatic cancer transplanted in the pancreas and subcutaneous region].
Ohyama K; Koike D; Odake Y; Takiyama Y; Saitoh T; Kagaya T; Takebe T; Ishii K
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2168-74. PubMed ID: 6307180
[TBL] [Abstract][Full Text] [Related]
4. [5-FU concentration in brain tumors after co-administration of FT and uracil].
Nogaki H; Taomoto K; Tamaki N; Matsumoto S
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 1):1007-12. PubMed ID: 6307160
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
6. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
[TBL] [Abstract][Full Text] [Related]
8. [5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207].
Takeshita M; Ishikawa H; Seki M; Ikeya T; Miyamoto Y; Izuo M; Tozuka S; Usui R; Kaneko H
Gan No Rinsho; 1985 Oct; 31(13):1697-703. PubMed ID: 3935831
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. A study with a combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil.
Hanaue H; Kurosawa T; Kitano Y; Miyakawa S; Nemoto A; Yamamoto H; Asagoe T; Takada T; Yasuda H; Shikata J
Cancer; 1987 May; 59(9):1571-6. PubMed ID: 3103905
[TBL] [Abstract][Full Text] [Related]
10. [UFT concentration in various tissues from cancer patients].
Kasai Y; Nakanishi Y; Nishi H; Nishindai H; Yoshimoto M; Nakamura T; Hashimoto I; Sawada Y; Mikami J; Bekki E
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2130-8. PubMed ID: 6414381
[TBL] [Abstract][Full Text] [Related]
11. [Level of 5-FU in tumor tissues of the patients with head and neck malignant tumors after oral administration of UFT].
Kusama M; Utsunomiya Y; Ono T; Nagura H; Enomoto S
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1796-802. PubMed ID: 6411004
[TBL] [Abstract][Full Text] [Related]
12. [5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration].
Tanimura T; Kaneshige E; Fujiwara K; Kobashi Y; Inoue K; Kono I; Sekiba K
Gan To Kagaku Ryoho; 1986 Feb; 13(2):349-55. PubMed ID: 3080967
[TBL] [Abstract][Full Text] [Related]
13. [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy].
Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):760-8. PubMed ID: 6424581
[TBL] [Abstract][Full Text] [Related]
14. [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
Suenaga M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3313-8. PubMed ID: 2825604
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermia enhances the inhibition of tumor growth by 1-(2-tetrahydrofuryl)-5-fluorouracil/uracil (1:4) in tumors in mice and humans.
Emi Y; Kohnoe S; Yoshida M; Takahashi I; Maehara Y; Sugimachi K
Cancer; 1992 Sep; 70(5):1177-82. PubMed ID: 1515994
[TBL] [Abstract][Full Text] [Related]
16. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
17. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
18. [FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
Oguma S; Sakai K; Sato R; Ouchi K; Owada Y; Sato T
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1122-8. PubMed ID: 3032114
[TBL] [Abstract][Full Text] [Related]
19. [Studies on 5-FU concentration in serum and bladder tumor tissue after oral administration of UFT].
Takayama H; Konami T; Konishi T; Pak K; Tomoyoshi T
Hinyokika Kiyo; 1986 Oct; 32(10):1449-53. PubMed ID: 3105272
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Kuwata K; Nagayama S; Hirakawa Y; Matsushima E; Kawaguchi Y
Gan To Kagaku Ryoho; 2000 Jun; 27(6):885-90. PubMed ID: 10897216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
